Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a drug called omalizumab (brand name 'Xolair') as a
potential treatment to be used in conjunction with drug desensitization to prevent reactions
from recurring and allowing the participant to be treated with the chemotherapy the
participant's oncologist prefers to give.